Some places are moving to universal early algebra. Minnesota has required it for years — with less-than-promising results.

Cabaletta Bio’s financials and CAR T-cell therapy show potential but face risks. Discover why CABA stock is a risky yet ...

The goal of universal early algebra is to get more students to take calculus in high school. Minnesota has tried it for years — with less-than-promising results.

THUNDER BAY, ON / ACCESSWIRE / January 7, 2025 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSX.V:AIR)(FRA:CKU)(OTCQB:CLRMF) is pleased to announce that a 2000-metre drilling program ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today annou ...

"These results firmly position our Khan project as a game-changer in the uranium industry," said Duane Parnham, Executive Chairman and CEO of Critical One. "With exceptional recovery rates and ...

Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ...

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR ) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR ), today announced significant progress in ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

Reliable exposure to long-term corporate ... investment-grade long credit analyst ranks, but it remains well-resourced. Vanguard's internal fixed-income team took over a roughly 10% sleeve of ...

Unlike other TROP2 ADCs in Phase 3, no cases of interstitial lung disease or Grade 3 and above stomatitis have been reported. Oqory’s Phase 3 studies ... business conditions; and the risks and ...